Actively Recruiting

Phase 2
Age: 18Months - 18Years
All Genders
NCT06933394

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2025-04-18

92

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of the combination therapy involving arsenic trioxide, MAPK inhibitors, and chemotherapy for stage 4/M neuroblastoma.

CONDITIONS

Official Title

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Who Can Participate

Age: 18Months - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a pathological diagnosis of neuroblastoma.
  • Preoperative staging as INRG M stage or postoperative staging as INSS stage 4 (regardless of risk classification).
  • Age 18 months to 18 years.
  • Informed consent obtained from the legal guardian with a signed consent form.
Not Eligible

You will not qualify if you...

  • History of other tumors treated with chemotherapy and abdominal radiation therapy.
  • Severe progressive or persistent heart failure: NYHA class III or IV or left ventricular ejection fraction below 50%.
  • Severe progressive or persistent kidney failure: glomerular filtration rate below 30 ml/(min·1.73 m²) or serum creatinine above 5 mg/dL (442 µmol/L).
  • Severe liver dysfunction: AST or ALT levels at least 5 times the upper limit of normal or total bilirubin at least 3 times the upper limit of normal.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-sen Memorial Hospital

Guangzhou, Guangdong, China, 510120

Actively Recruiting

Loading map...

Research Team

Y

Yang Li, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here